Signateraā¢ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). The study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current standard of care. It prospectively incorporates Signatera, Nateraās personalized, tumor-informed molecular residual diseas
Related Questions
How will the inclusion of the Signatera test in the ARCHER trial affect Natera's revenue forecasts and earnings guidance?
What are the potential regulatory and market adoption timelines for the Signatera test based on the trial outcomes?
How does this partnership with NRG Oncology position Natera relative to competitors in the liquid biopsy and precision oncology space?